Document Detail


Antihypertensive treatment with cilazapril. Resting and exercise blood pressure, hormones and enzymes.
MedLine Citation:
PMID:  2159308     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The effects of the angiotensin-converting enzyme (ACE) inhibitor cilazapril (Ro 31-2848) on resting and exercise blood pressure (BP) as well as on hormonal and enzyme activities were evaluated following a more than one year long-term treatment. After an initial placebo wash-out (mean sitting BP 151/101), n = 13 hypertensive patients were on cilazapril treatment (1.25, 2.5 or 5 mg/d; in 2 cases with 25 mg hydrochlorothiazide additionally) for 78 (70 to 82) weeks (phase A, mean sitting BP 137/91). Thereafter, they underwent a second placebo wash-out of 4.4 (1 to 10) weeks (phase B, mean sitting BP 137/94) again followed by cilazapril treatment of 9.5 (4 to 14) weeks (phase C, mean sitting BP 137/91) to titrate the minimum antihypertensive dose. At the end of each phase, blood pressure was measured at rest and during isotonic (bicycle) and isometric (handgrip) exercise, and hormones and enzymes were evaluated 4 h post-dose.
Authors:
K Breithaupt; G G Belz; D G Spielmanns; W Neis; P Kirchner
Related Documents :
10777028 - Marked weight reduction lowers resting and exercise blood pressure in morbidly obese su...
10945878 - Consequence of exercise on the cardiovascular effects of l-propranolol in spontaneously...
2724538 - The significance of abnormal systolic blood pressure response during supine ergometer e...
1920338 - Correlations between left ventricular mass and systolic blood pressure at rest and duri...
23178748 - Running-induced epigenetic and gene expression changes in the adolescent brain.
8175538 - Inhaled furosemide attenuates hyperpnea-induced obstruction and intra-airway thermal gr...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Arzneimittel-Forschung     Volume:  40     ISSN:  0004-4172     ISO Abbreviation:  Arzneimittelforschung     Publication Date:  1990 Feb 
Date Detail:
Created Date:  1990-06-04     Completed Date:  1990-06-04     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  0372660     Medline TA:  Arzneimittelforschung     Country:  GERMANY, WEST    
Other Details:
Languages:  eng     Pagination:  136-41     Citation Subset:  IM    
Affiliation:
Center for Cardiovascular Pharmacology ZeKaPha GmbHa, Mainz-Wiesbaden, Federal Republic of Germany.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Angiotensin-Converting Enzyme Inhibitors / adverse effects,  therapeutic use*
Antihypertensive Agents / adverse effects,  therapeutic use*
Blood Pressure / drug effects*
Cilazapril
Enzymes / blood
Exercise
Female
Heart Rate / drug effects
Hormones / blood
Humans
Hypertension / drug therapy*,  physiopathology
Male
Middle Aged
Peptidyl-Dipeptidase A / blood
Pyridazines / adverse effects,  therapeutic use*
Chemical
Reg. No./Substance:
0/Angiotensin-Converting Enzyme Inhibitors; 0/Antihypertensive Agents; 0/Enzymes; 0/Hormones; 0/Pyridazines; 92077-78-6/Cilazapril; EC 3.4.15.1/Peptidyl-Dipeptidase A

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Mechanism of inactivation of myeloperoxidase by propylthiouracil.
Next Document:  Potential proteolytic activity of human plasma fibronectin: fibronectin gelatinase.